In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
491 News Items found
A chess match
In the Lab
Resistance Is Futile: Targeted Treatment Makes Stubborn Cancers Responsive to Immunotherapy

New research on an experimental drug provides hope for better responses to immunotherapy.
Lymph nodes and lymphatic vessels with adjacent blood vessels
Finding
Definitive Study Shows That People with Melanoma Do Not Need Immediate Lymph Node Removal

The results of a large, international randomized trial herald a change in medical practice for the treatment of melanoma.
MSK Nassau
Feature
7 Reasons to Come to MSK Nassau for Cancer Care

Learn more about world-class cancer care on Long Island at MSK Nassau.
Lymphedema can produce uncomfortable swelling in the arms or legs in the months and years following cancer treatment.
In the Lab
Could a Topical Cream Prevent Lymphedema? Study in Mice Suggests Yes

By blocking a source of inflammation in the skin, it may be possible to prevent or treat lymphedema, a common and debilitating cancer complication.
Memorial Sloan Kettering surgeon Prasad Adusumilli
Q&A
CAR T Cell Therapy Shows Promise for Treating Mesothelioma

A combination immunotherapy approach using CAR T cells could be an effective new way to treat mesothelioma.
Dr. Craig Thompson in his lab at the Sloan Kettering Institute
New MSK Research Reveals How Mitochondria Function Under Stress Like Cancer

Mitochondria provide both the energy cells need to survive and the building blocks they need to grow and divide. Researchers at the Sloan Kettering Institute reveal for the first time how mitochondria choose between these opposing paths — and what implications it may have for cancer.
A hand holding a thin optical fiber giving off a red light.
In the Clinic
Light-Activated Drug Destroys Small Prostate Cancers with Fewer Side Effects

A novel treatment for prostate cancer involves a light-sensitive drug that destroys small tumors and the blood vessels that feed them.
Yonina Murciano-Goroff, Jenny Xue, Bob Li, Piro Lito, and Yulei Zhao.
Finding
MSK Researchers Are Learning Why Some Patients Develop Resistance to Targeted Lung Cancer Drug

A paper from MSK researchers reports that resistance to sotorasib, a new targeted drug for lung cancer, can be caused by many different molecular changes.
A researcher working in an MSK lab
MSK Research Highlights, April 27, 2026

New MSK research shows how pancreatic cancer cells organize themselves to fuel tumor growth; finds an antibody-drug conjugate shows efficacy in rare pediatric sarcoma; develops an AI tool could accelerate identification of disease-causing genetic variants; and builds quantum nanosensors for cancer blood tests.
Participants in Cycle for Survival
Treating Rare Cancers

Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.